EMA Authorised: Invokana (canagliflozin) — Janssen-Cilag International NV

View source ↗

Summary

The EMA has authorised Invokana (canagliflozin) for use in Type 2 diabetes mellitus; the marketing authorization holder is Janssen-Cilag International NV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Janssen-Cilag International NV. Decision date: 22/08/2025